Can drug treatments enhance learning in subjects with intellectual disability?

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 10, 2009, Pages 899-904

  Glue, Paul ^a   Patterson, Tess ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Down syndrome; Drug treatment; Fragile X syndrome; Intellectual disability

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ACETYLCHOLINE; BACLOFEN; CHOLINESTERASE INHIBITOR; DOPAMINE; FENOBAM; FLUOXETINE; FRAGILE X MENTAL RETARDATION PROTEIN; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GLUTAMIC ACID; HISTAMINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; METHYLPHENIDATE; NORADRENALIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ACETYLCHOLINE BRAIN LEVEL; COGNITION; DOPAMINE BRAIN LEVEL; DOWN SYNDROME; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FRAGILE X SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; LEARNING; METHODOLOGY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN BRAIN LEVEL; PROTEIN FUNCTION; REVIEW; SEIZURE; SEROTONIN BRAIN LEVEL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 71049137199     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670903179178     Document Type: Review

References (59)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn.Washingt on, DC: American Psychiatric Association, 2000.
2. Ramey CT, Ramey SL. Early intervention and early experience. Am Psychol 1998; 53:109-120.
3. 3.Chapman RS, Hesketh LJ. Behavioural phenotype of individuals with Down syndrome. Ment Retardation Dev Disabil Res Rev 2000; 6:84-95.
4. 4.Nirje B. The basis and logic of the normalization principle. ANZ J Dev Disabil 1985; 2:65-68.
5. 5.Ryba K, Fraser D, Moltzen R. Learners with special needs in Aotearoa New Zealand, 3rd edn.Palmersto n North, NZ: Thomson Learning Nelson, 2005.
6. 6.Conners FA, Rosenquist CJ, Arnett L, Moore MS, Hume LE. Improving memory span in children with Down Syndrome. J Intellect Disabil Res 2008; 52:244-255.
7. 7.Connolly BH, Morgan SB, Russell FF, Fulliton WL, Shea AM.A longitudinal study of children with Down syndrome who experienced early intervention programming. Physical Ther 1993; 73:170-181.
8. 8.Laws G, McDonald J, Buckley S. The effects of a short training in the use of a rehearsal strategy on memory for words and pictures in children with Down syndrome. Down's Syndrome: Res Pract 1996; 4:70-78.
9. 9.Plomin R. The quest for quantitative trait loci associated with intelligence. Intelligence 2006; 34:513-526.
10. 10.Kramer JM, van Bokhoven H.Genetic and epigenetic defects in mental retardation. Int J Biochem Cell Biol 2009; 41:96-107.
11. 11.Ropers HH. Genetics of intellectual disability. Curr Opin Genet Dev 2008; 18:241-250
12. 12.Best TK, Siarey RJ, Galdzicki Z. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABA-B-induced potassium current. J Neurophysiol 2007; 97:892-900.
13. 13.Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S et al.SGS742: the first GABA(B) receptorantagonist in clinical trials. Biochem Pharmacol 2004; 68:1479-1487.
14. 14.Fernandez F, Morishita W, Zuniga E et al.Pharma cotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10:411-413. (Pubitemid 46494581)
15. 15.Nutt DJ, Glue P. Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. Pharmacol Ther 1989; 44:309-334.
16. 16.Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond. Neurosci 2006; 26:7151-7155.
17. 17.Weiler IJ, Spangler CC, Klintsova AY et al.Fragile X mental retardation protein is necessary for neurotransmitteractivated protein translation at synapses. Proc Natl Acad Sci USA 2004; 101:17504-17509.
18. 18.Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005; 49:1053-1066.
19. 19.Dolen G, Osterweil E, Rao BS et al.Correction of fragile X syndrome in mice. Neuron 2007; 56:955-962.
20. 20.Berry-Kra vis E, Hessl D, Coffey S et al.A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009; 46:266-271.
21. 21.de Vrij FMS, Levenga J, van der Linde HC et al.Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008; 31:127-132.
22. 22.Hessl D, Berry-Kravis E, Cordeiro L et al.Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment Am J Med Genet B Neuropsychiatr Genet 2009; 150B:545-553.
23. 23.Berger-Sween ey J, Hohmann CF. Behavioral consequences of abnormal cortical development: insights into developmental disabilities. Behav Brain Res 1997; 86:121-142.
24. 24.Thompson BL, Levitt P, Stanwood GD.Prenatal exposure to drugs: effects on brain development and implications for policy and education. Nat Rev Neurosci 2009; 10:303-312.
25. 25.Smigielska- Kuzia J, Sobaniec W. Brain metabolic profile obtained by proton magnetic resonance spectroscopy H-MRS in children with Down syndrome. Adv Med Sci 2007; 52:183-187.
26. 26.Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics 2007; 120:1465-1471.
27. 27.Kish S, Karlinksy H, Becker L, Gilbert J, Rebbetoy M, Chang LJ.Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 1989; 52:1183-1187.
28. 28.Florez J, del Arco C, Gonzalez A, Pascual J, Pazos A. Autoradiographic studies of neurotransmitter receptors in the brain of newborn infants with Down syndrome. Am J Genet Suppl 1990; 7:301-305.
29. 29.Le verenz JB, Raskind MA.Amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998; 150:296-304.
30. 30.McGeer EG, Norman M, Boyes B, O'Kusky J, Suzuki J, McGeer PL.Acetylcholin e and aromatic amine systems in post-mortem brain of an infant with Down's syndrome. Exp Neurol 1985; 87:557-570.
31. 31.Schneider C, Risser D, Kirchner L et al.Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neurosci Lett 1997; 222:183-186.
32. 32.Clark S, Schwalbe J, Stasko MR, Yarowsky PJ, Costa AC. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 2006; 200:256-261.
33. 33.Zarrindast MR. Neurotransmitters and cognition. In: Levin ED, ed. Neurotransmitter interactions and cognitive function. Basel: Birkhauser Verlag, 2006:5-40.
34. 34.Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Li JS, Kishnani PS.Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Am J Med Genet 2006; 142(C):187-195.
35. Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS.Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. Am J Med Genet 2004; 130(A):325-326.
36. 36.Spiridigliozz i GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells R, Dawson D.Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a case report series. Am J Med Genet 2007; 143A:1408-1413.
37. 37.Clinicaltrials. gov. Evaluating the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome. Bethesda: National Institutes of Health, 2008. [cited 15 April 2009.] Available from URL: http:// clinicaltrials.gov/ct2/show/ NCT00754013; http:// clinicaltrials.gov/ct2/show/NCT00754052.
38. 38.Aman MG, Marks RE, Turbott SH, Wilsher CP, Merry SN. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 1991; 30:816-824.
39. 39.Pearson DA, Santos CW, Casat CD et al.Treatmen t effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43:677-685.
40. 40.Newey SE, Velamoor V, Govek EE, Van Aelst L.Rho GTPases, dendritic structure, and mental retardation. J Neurobiol 2005; 64:58-74.
41. 41.Ramakers GJ. Rho proteins, mental retardation and the cellular basis of cognition. Trends Neurosci 2002; 25:191-199.
42. 42.Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147.
43. 43.Conn PJ, Tamminga C, Schoepp DD, Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol Interv 2008; 8:99-107.
44. 44.Youdim MBH, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26:27-35.
45. National Institutes of Health. National Institutes of Health Research Plan on Down Syndrome 2007.Bethesd a: National Institutes of Health, 2007.[cited 15 March 2009]. Available from URL: http://wwwnichd.nih.gov/publications/pubs/ upload/NIH-downsyndrome-plan.pdf.
46. 46.Couzens D, Cuskelly M, Jobling A. The Stanford Binet Fourth Edition and its use with individuals with Down syndrome: cautions for clinicians. Int J Disabil Dev Educ 2004; 51:39-56.
47. 47.McKenzie K, Harte C, Sinclair E, Matheson E, Patrick S, Murray GC.An examination of the severe impairment battery as a measure of cognitive decline in clients with Down's syndrome. J Intellect Disabil 2002; 6:89-96.
48. Silverman W. Down Syndrome: cognitive phenotype. Ment Retardation Dev Disabil Res Rev 2007; 13:228-236.
49. 49.Hick RF, Botting N, Conti-Ramsden G. Short-term memory and vocabulary in development in children with Down syndrome and children with specific language impairment. Dev Med Child Neurol 2005; 47:532-538.
50. 50.Vicari S, Bellucci S, Carlesimo GA. Evidence from two genetic syndromes for the independence of spatial and visual working memory. Dev Med Child Neurol 2006; 48:126-131.
51. 51.Laws G. Working memory in children and adolescents with Down syndrome: evidence from a colour memory experiment. J Child Psychol Psychiatry 2002; 43:353-364.
52. 52.Patterson D. Genetic mechanisms involved in the phenotype of Down syndrome. Ment Retardation Dev Disabil Res Rev 2007; 13:199-206.
53. 53.Green P, Flaro F. Word memory test performance in children. Child Neuropsychol 2003; 9:189-207.
54. 54.Wishart JG. Cognitive abilities in children with Down syndrome; developmental instability and motivational deficits. Prog Clin Biol Res 1995; 393:57-91.
55. 55.Dierssen M, Ortiz-Abalia J, Arque G, Martinez de Lagran M, Fillat C.Pitfalls and hopes in Down syndrome therapeutic approaches; in the search for evidence-based treatments. Behav Genet 2006; 36:454-468.
56. 56.Carr A, O'Reilly G. Interviewing and report writing.In: Carr A, O'Reilly G, Walsh PN, McEvoy J, eds. The handbook of intellectual disability and clinical psychology practice.London: Routledge, 2007:169-227.
57. 57.Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA.Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry 2005; 44:748-755.
58. 58.Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 1999; 38:805-812.
59. 59.Handen BL, Breaux AM, Janosky J, McAuliffe S, Felman H, Gosling A.Effects and noneffects of methylphenidate in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 1992; 30:241-245.